ARSB and melanoma: Recent work demonstrated that exogenous, bioactive ARSB reduced the progression and improved the survival of mice with B16F10 subcutaneous melanomas [6], and further evaluation of the potential therapeutic benefit of exogenous ARSB treatment is warranted.